Does Rallies show 13F holders for APLS?

Yes. Rallies tracks hedge fund and 13F ownership data for APLS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is APLS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for APLS. It does not provide personalized investment advice.

APLS (Apellis Pharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Apellis Pharmaceuticals, Inc. Common Stock (APLS) is a publicly traded Healthcare sector company. As of May 21, 2026, APLS trades at $41.03 with a market cap of $5.25B and a P/E ratio of -25.64. APLS moved -0.04% today. Year to date, APLS is +64.32%; over the trailing twelve months it is +137.44%. Its 52-week range spans $16.10 to $41.14. Analyst consensus is neutral with an average price target of $39.50. Rallies surfaces APLS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns APLS stock?

Hedge funds tracked by Rallies that own APLS include Pentwater Capital, Orbimed Advisors, Soros Fund, Redmile Group, and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Apellis Pharmaceuticals, Inc. Common Stock.

APLS Key Metrics

Key financial metrics for APLS
Metric	Value
Price	$41.03
Market Cap	$5.25B
P/E Ratio	-25.64
EPS	$-1.60
Dividend Yield	0.00%
52-Week High	$41.14
52-Week Low	$16.10
Volume	0
Avg Volume	0
Revenue (TTM)	$781.37M
Net Income	$-197.88M
Gross Margin	0.00%

Top Hedge Funds Holding APLS

Pentwater Capital holds 5.25M shares of APLS, changed +0.00% as of Mar 31, 2026.
Orbimed Advisors holds 2.43M shares of APLS, changed +4.58% as of Dec 31, 2025.
Soros Fund holds 1.06M shares of APLS, changed +11701.52% as of Mar 31, 2026.
Redmile Group holds 155.00K shares of APLS, changed +0.00% as of Mar 31, 2024.
Centerbook Partners holds 50.69K shares of APLS, changed +0.00% as of Sep 30, 2024.

Latest APLS News

Biogen Finalizes $5.3B Acquisition of Apellis, Gains $689M Drugs — May 15, 2026
Apellis to Exit S&P SmallCap 600 on May 14 as Q1 EPS Tops Estimates — May 7, 2026
Apellis to Be Acquired by Biogen for $41 Cash and $4 CVR — Apr 20, 2026
Biogen to Buy Apellis for $5.6B at 140% Premium, Adding $689M Revenue — Apr 1, 2026
Apellis Appoints Ex-Pfizer CSO Dolsten to Board, Oversaw 36 Approvals — Mar 2, 2026

Recent APLS Insider Trades

DeLong Mark Jeffrey sold 368 (~$8.15K) on Feb 11, 2026.
Baumal Caroline sold 2.80K (~$60.88K) on Jan 22, 2026.
Chopas James George sold 2.06K (~$44.92K) on Jan 22, 2026.

APLS Analyst Consensus

18 analysts cover APLS: 0 strong buy, 2 buy, 16 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $39.50.

Common questions about APLS

Who owns APLS stock?: Hedge funds tracked by Rallies that own APLS include Pentwater Capital, Orbimed Advisors, Soros Fund, Redmile Group, and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Apellis Pharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for APLS?: Yes. Rallies tracks hedge fund and 13F ownership data for APLS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is APLS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for APLS. It does not provide personalized investment advice.